University of Alabama at Birmingham, Birmingham, Alabama, USA.
University of Minnesota, Minneapolis, Minnesota, USA.
Obesity (Silver Spring). 2020 Feb;28(2):247-258. doi: 10.1002/oby.22676. Epub 2020 Jan 3.
To examine the effects of an intensive lifestyle intervention (ILI) on cardiovascular disease (CVD), the Action for Health in Diabetes (Look AHEAD) trial randomized 5,145 participants with type 2 diabetes and overweight/obesity to a ILI or diabetes support and education. Although the primary outcome did not differ between the groups, there was suggestive evidence of heterogeneity for prespecified baseline CVD history subgroups (interaction P = 0.063). Event rates were higher in the ILI group among those with a CVD history (hazard ratio 1.13 [95% CI: 0.90-1.41]) and lower among those without CVD (hazard ratio 0.86 [95% CI: 0.72-1.02]).
This study conducted post hoc analyses of the rates of the primary composite outcome and components, adjudicated cardiovascular death, nonfatal myocardial infarction (MI), stroke, and hospitalization for angina, as well as three secondary composite cardiovascular outcomes.
Interaction P values for the primary and two secondary composites were similar (0.060-0.064). Of components, the interaction was significant for nonfatal MI (P = 0.035). This interaction was not due to confounding by baseline variables, different intervention responses for weight loss and physical fitness, or hypoglycemic events. In those with a CVD history, statin use was high and similar by group. In those without a CVD history, low-density lipoprotein cholesterol levels were higher (P = 0.003) and statin use was lower (P ≤ 0.001) in the ILI group.
Intervention response heterogeneity was significant for nonfatal MI. Response heterogeneity may need consideration in a CVD-outcome trial design.
研究强化生活方式干预(ILI)对心血管疾病(CVD)的影响,糖尿病行动研究(Look AHEAD)试验将 5145 名 2 型糖尿病合并超重/肥胖患者随机分为 ILI 组或糖尿病支持和教育组。尽管两组的主要结局无差异,但对预先设定的 CVD 病史亚组存在提示性异质性(交互 P=0.063)。ILI 组有 CVD 病史的患者事件发生率较高(危险比 1.13 [95% CI:0.90-1.41]),无 CVD 病史的患者事件发生率较低(危险比 0.86 [95% CI:0.72-1.02])。
本研究对主要复合结局和各组分、心血管死亡、非致死性心肌梗死(MI)、卒中和稳定性心绞痛住院的发生率以及三个次要复合心血管结局进行了事后分析。
主要和两个次要复合的交互 P 值相似(0.060-0.064)。各组分中,非致死性 MI 的交互作用有统计学意义(P=0.035)。这种交互作用不是由于基线变量的混杂、减肥和体能干预反应的不同或低血糖事件造成的。在有 CVD 病史的患者中,他汀类药物的使用率较高且两组之间无差异。在无 CVD 病史的患者中,ILI 组的低密度脂蛋白胆固醇水平较高(P=0.003)且他汀类药物使用率较低(P≤0.001)。
非致死性 MI 的干预反应异质性显著。在 CVD 结局试验设计中可能需要考虑这种异质性。